Moreno-Rodríguez Adriana, Campo-Colín Ada Sarai Martin Del, Domínguez-Díaz Luis Roberto, Posadas-Jiménez Ana Livia, Matadamas-Martínez Félix, Yépez-Mulia Lilián
Laboratorio de Estudios Epidemiológicos, Clínicos, Diseños Experimentales e Investigación, Facultad de Ciencias Químicas, Universidad Autónoma "Benito Juárez" de Oaxaca, Avenida Universidad S/N, Ex Hacienda Cinco Señores, Oaxaca 68120, Mexico.
Unidad de Investigación Médica en Enfermedades Infecciosas y Parasitarias, UMAE Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City 06720, Mexico.
Microorganisms. 2025 Jan 21;13(2):220. doi: 10.3390/microorganisms13020220.
Pentavalent antimonials are the first line for leishmaniasis treatment, although they induce many adverse side effects and treatment failure and parasite resistance have been detected. Cutaneous leishmaniasis is the main clinical manifestation of the disease in Oaxaca State, Mexico; however, its presence is under-registered, and information about the species that circulate and cause the disease in the region is limited. In this study, the presence of was analyzed in 24 skin smears and 2 biopsies from lesions suspicious for leishmaniasis in inhabitants of the Tehuantepec Isthmus and Papaloapan Basin regions, Oaxaca State. By ITS1-PCR, the species of clinical isolates were identified. Moreover, the susceptibility of clinical isolates to leishmanicidal drugs was assessed. Skin smears were negative for the presence of spp.; meanwhile, parasite amastigotes were observed in tissue biopsies; however, by ITS1-PCR, 46% of the samples were determined to be positive for the parasite. Six clinical isolates were identified as and had lower susceptibility to Miltefosine and Amphotericin B than the reference strain. No leishmanicidal activity of Glucantime was detected. Further studies with increased patient sample sizes and genotypic studies will describe in detail parasite susceptibility to reference drugs in the region.
Mediterr J Hematol Infect Dis. 2022-7-1
Adv Biomed Res. 2017-3-1
Metabolites. 2025-8-21
J Clin Lab Anal. 2022-8
Actas Dermosifiliogr (Engl Ed). 2021-5-11